Unintended Interruption of Caplacizumab Therapy Can Compromise Outcomes in Immune-Mediated Thrombotic Thrombocytopenic Purpura: Lessons from Two Clinical Cases. (PubMed, J Clin Med) - Sep 16, 2026 - "Treatment escalation to PEX and rituximab and reinitiation of continuous caplacizumab administration led to clinical stabilization. Even brief interruptions of caplacizumab therapy may compromise outcomes in iTTP. Continuous administration and secured availability, together with serial monitoring of ADAMTS13 activity to guide treatment duration and discontinuation, are essential to improve patient care."
Journal • Hematological Disorders • Ischemic stroke • Thrombocytopenia • Thrombocytopenic Purpura
|
|
Alexandra Brinkhoff; Fahri Kiziler; Fedai Özcan; Lucas Kühne; Paul Brinkkoetter; Paul Knöbl
|